Abstract
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: The primary objective is to assess the safety and efficacy of milrinone (with or without concomitant use of other inotropes) compared with placebo or no treatment for the treatment of neonates with cardiac dysfunction. Sub group analysis will be undertaken if data permit to identify the effects of milrinone in subgroups according to Gestational age: preterm <32 weeks gestation Aetiology for dysfunction: associated with or secondary to pulmonary hypertension Type of dysfunction: diastolic dysfunction ‐ diagnosed using Tissue doppler measurement of Ew/Aw <1 Dosage regimen: continuous infusion of high dose (>0.5 mcg/kg/min), low dose (<0.5 mcg/kg/min) Concomitant inotropes: milrinone used as the single agent in the treatment of cardiac dysfunction (i.e. without the use of concomitant inotropes)
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
